A5034582186- Head and Neck Cancer Studies
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Thyroid Cancer Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Head and Neck Surgical Oncology
- Salivary Gland Tumors Diagnosis and Treatment
- Ear and Head Tumors
- Oral health in cancer treatment
- Colorectal and Anal Carcinomas
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Radiopharmaceutical Chemistry and Applications
- Immunotherapy and Immune Responses
- Cancer survivorship and care
- SARS-CoV-2 and COVID-19 Research
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- CAR-T cell therapy research
- Radiomics and Machine Learning in Medical Imaging
- Dysphagia Assessment and Management
- Brain Metastases and Treatment
- Neuroendocrine Tumor Research Advances
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
Kobe University Hospital
2016-2025
Kobe University
2015-2024
National Cancer Center
2012-2024
Kansai Medical University
2024
Kobe Institute Of Computing
2023
National Cancer Center Hospital East
2007-2022
Pfizer (United Kingdom)
2021-2022
Eisai (Japan)
2021-2022
Novartis (Switzerland)
2021-2022
Ono Pharmaceutical (United Kingdom)
2021-2022
Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition.In randomized, open-label, phase 3 trial, we assigned, in 2:1 ratio, 361 patients whose disease had progressed within 6 months platinum-based to receive nivolumab (at dose mg per kilogram body weight) every 2 weeks...
Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast 1 through 4, platelet-derived receptor α, RET, KIT, showed clinical activity in a phase 2 study involving patients with differentiated thyroid cancer that was refractory to radioiodine (iodine-131).In our randomized, double-blind, multicenter progressive iodine-131, we randomly assigned 261 receive lenvatinib (at daily dose 24 mg per day 28-day cycles) 131 placebo. At the time disease...
PURPOSE The standard treatment for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) is chemoradiotherapy with 3-weekly cisplatin (100 mg/m 2 ). However, whether weekly (40 ) yields comparable efficacy in LA-SCCHN unknown. PATIENTS AND METHODS In this multi-institutional open-label phase II/III trial, patients were randomly assigned to receive either or confirm noninferiority cisplatin. primary end point II was proportion completion, that III...
Abstract Background To evaluate factors associated with osteoradionecrosis of the jaw (ORNJ) in patients head and neck squamous cell carcinoma (HNSCC), focusing on jaw-related dose–volume histogram (DVH) parameters. Methods We retrospectively reviewed medical records 616 HNSCC treated curative-intent or postoperative radiation therapy (RT) during 2008–2018. Patient-related (age, sex, history smoking alcohol use, diabetes mellitus, performance status, pre-RT dental evaluation, pre- post-RT...
CheckMate 651 (ClinicalTrials.gov identifier: NCT02741570) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab cisplatin/carboplatin fluorouracil ≤ six cycles, then cetuximab maintenance) in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Lenvatinib has been approved by regulatory agencies in Japan, the United States, and European Union for treatment of radioiodine-refractory differentiated thyroid cancer (RR-DTC). Thyroid cancer, however, is a clinically diverse disease that includes anaplastic (ATC), subtype associated with highest lethality. Effective therapy ATC an unmet need.This phase 2, single-arm, open-label study patients including ATC, RR-DTC, medullary was conducted from 3 September 2012 to 9 July 2015. Patients...
To investigate the safety and efficacy of lenvatinib in advanced thyroid cancer.In this Phase II study, 51 Japanese patients with radioiodine-refractory differentiated cancer (RR-DTC), medullary (MTC) or anaplastic (ATC) received once-daily 24 mg. The primary end point was safety.All experienced ≥1 adverse event (AE); only one patient an AE leading to discontinuation. most common any-grade AEs were hypertension, decreased appetite, palmar-plantar erythrodysesthesia, fatigue proteinuria....
Lenvatinib significantly prolonged progression-free survival (PFS) versus placebo in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC) the phase 3 Study of (E7080) Differentiated Cancer Thyroid (SELECT) trial. This subanalysis evaluated efficacy and safety lenvatinib Japanese who participated SELECT. Outcomes for (lenvatinib, n = 30; placebo, 10) were assessed relationship to SELECT population 261; 131). The primary endpoint was PFS; secondary endpoints included...
To assess efficacy and safety of nivolumab versus investigator's choice therapy (IC) in Asian patients with platinum-refractory recurrent or metastatic squamous cell carcinoma the head neck (SCCHN). Thirty-four from Japan, Taiwan, Hong Kong, Korea received 3 mg/kg (n = 23) every 2 weeks IC 11), as part a global trial 361), until intolerable toxicity disease progression. The primary endpoint was overall survival (OS). Median OS 9.5 months (95% confidence interval [CI] 9.1–NR) 6.2 CI 2.6–NR)...
Abstract Background We validated the new European Organisation for Research and Treatment of Cancer Quality Life Head Neck Module (EORTC QLQ‐HN43). Methods enrolled 812 patients with head neck cancer from 18 countries. Group 1 completed questionnaire before therapy, 3 6 months later. In group 2 (survivors), we determined test–retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed Cronbach's Alpha, scale structure confirmatory factor analysis,...
BACKGROUND Hypertension (HTN) is an established class effect of vascular endothelial growth factor receptor (VEGFR) inhibition. In the phase 3 Study (E7080) Lenvatinib in Differentiated Cancer Thyroid (SELECT) trial, HTN was most frequent adverse event lenvatinib, inhibitor VEGFR1, VEGFR2, VEGFR3, fibroblast 1 (FGFR1), FGFR2, FGFR3, FGFR4, platelet‐derived α (PDGFRα), ret proto‐oncogene (RET), and stem cell (KIT). This exploratory analysis examined treatment‐emergent hypertension (TE‐HTN)...
Abstract Background To promote precision oncology in clinical practice, the Japanese Society of Medical Oncology, Clinical and Cancer Association, jointly published “Clinical practice guidance for next-generation sequencing cancer diagnosis treatment” 2017. Since new information on genomic medicine has emerged since 1st edition was released, including reimbursement NGS-based multiplex gene panel tests 2019, revision made. Methods A working group organized with 33 researchers from designated...
In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival (OS) versus investigator's choice (IC) of chemotherapy at primary analysis among 361 patients with recurrent or metastatic squamous cell carcinoma head and neck (R/M SCCHN) post-platinum therapy. Nivolumab IC as first-line treatment also OS R/M SCCHN who progressed on platinum therapy for locally advanced disease in adjuvant setting 1-year follow-up. present long-term follow-up receiving...
Abstract Head and neck cancer (HNC) patients suffer from a range of health‐related quality life (HRQoL) issues, but little is known about their long‐term HRQoL. This study explored associations between treatment group HRQoL at least 5 years' post‐diagnosis in HNC survivors. In an international cross‐sectional study, survivors completed the European Organization for Research Treatment Cancer (EORTC) core questionnaire (EORTC‐QLQ‐C30) its module (EORTC‐QLQ‐H&N35). Meaningful differences...
An important unmet need for new treatment options remains patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) previously treated both platinum-based chemotherapy anti-programmed death protein 1 (PD-1) antibody. Retrospective studies suggest that previous immune checkpoint inhibitor might augment the efficacy of subsequent chemotherapy. Here, we conducted a phase II trial aimed to evaluate safety paclitaxel plus biweekly cetuximab in this setting.
The standard of care for first-line treatment recurrent and/or metastatic squamous cell carcinoma the head and neck (R/M SCCHN) is combination with platinum, 5-FU cetuximab (PFE). However, this regimen requires hospitalization to ensure proper hydration continuous infusion 5-FU, causes severe nausea anorexia. We evaluated efficacy safety paclitaxel, carboplatin (PCE) as in patients R/M SCCHN.Eligibility criteria included metastatic, histologically proven SCC oropharynx, oral cavity,...
Abstract Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma head and neck (SCCHN). Here, we report that OS benefit nivolumab was maintained a minimum follow-up 11.4 months. Further, IC also noted among who received first-line treatment for R/M SCCHN after progressing on platinum therapy locally advanced...
The objective of this study was to pilot test an updated version the European Organization for Research and Treatment Cancer Quality Life Questionnaire Head Neck Module (EORTC QLQ-H&N60).Patients with head neck cancer were asked complete a list 60 cancer-specific items comprising EORTC module core questionnaire QLQ-C30. Debriefing interviews conducted identify any irrelevant confusing or upsetting wording.Interviews performed 330 patients from 17 countries, representing different sites...